228 related articles for article (PubMed ID: 20549538)
1. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line.
Shi MF; Jiao J; Lu WG; Ye F; Ma D; Dong QG; Xie X
Cell Mol Life Sci; 2010 Nov; 67(22):3915-25. PubMed ID: 20549538
[TBL] [Abstract][Full Text] [Related]
2. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
3. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.
Meng E; Long B; Sullivan P; McClellan S; Finan MA; Reed E; Shevde L; Rocconi RP
Clin Exp Metastasis; 2012 Dec; 29(8):939-48. PubMed ID: 22610780
[TBL] [Abstract][Full Text] [Related]
4. Identification of CD44+CD24+ gastric cancer stem cells.
Zhang C; Li C; He F; Cai Y; Yang H
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1679-86. PubMed ID: 21882047
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma.
Han J; Fujisawa T; Husain SR; Puri RK
BMC Cancer; 2014 Mar; 14():173. PubMed ID: 24612587
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Mine T; Matsueda S; Li Y; Tokumitsu H; Gao H; Danes C; Wong KK; Wang X; Ferrone S; Ioannides CG
Cancer Immunol Immunother; 2009 Aug; 58(8):1185-94. PubMed ID: 19048252
[TBL] [Abstract][Full Text] [Related]
7. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
8. CD44
Hui D; Chen J; Jiang Y; Pan Y; Zhang Z; Dong M; Shao C
Exp Cell Res; 2020 May; 390(2):111968. PubMed ID: 32197932
[TBL] [Abstract][Full Text] [Related]
9. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Shi C; Tian R; Wang M; Wang X; Jiang J; Zhang Z; Li X; He Z; Gong W; Qin R
Cancer Biol Ther; 2010 Dec; 10(11):1182-90. PubMed ID: 20948317
[TBL] [Abstract][Full Text] [Related]
10. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
[TBL] [Abstract][Full Text] [Related]
11. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
12. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma.
Huang P; Wang CY; Gou SM; Wu HS; Liu T; Xiong JX
World J Gastroenterol; 2008 Jun; 14(24):3903-7. PubMed ID: 18609717
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Wei HJ; Yin T; Zhu Z; Shi PF; Tian Y; Wang CY
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):428-34. PubMed ID: 21813394
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
15. CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation.
Shen YA; Wang CY; Chuang HY; Hwang JJ; Chi WH; Shu CH; Ho CY; Li WY; Chen YJ
Oncotarget; 2016 Sep; 7(36):58351-58366. PubMed ID: 27521216
[TBL] [Abstract][Full Text] [Related]
16. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
[TBL] [Abstract][Full Text] [Related]
17. CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
Sun H; Jia J; Wang X; Ma B; Di L; Song G; Ren J
Clin Transl Oncol; 2013 Jan; 15(1):46-54. PubMed ID: 22855175
[TBL] [Abstract][Full Text] [Related]
18. Identification of pancreatic cancer stem cells.
Li C; Heidt DG; Dalerba P; Burant CF; Zhang L; Adsay V; Wicha M; Clarke MF; Simeone DM
Cancer Res; 2007 Feb; 67(3):1030-7. PubMed ID: 17283135
[TBL] [Abstract][Full Text] [Related]
19. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
[TBL] [Abstract][Full Text] [Related]
20. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]